Nuformix Plc (NFX) AI Stock Analysis

• Market Cap: £4.01M
• Dividend Yield: N/A
• Average Volume (3M): 97.88M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.10
• Revenue Growth: N/A
• EPS Growth: -616.67%
• Country: UK
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,109,750,000
• 10 Day Avg. Volume: 69,476,590
• 30 Day Avg. Volume: 97,880,797
• PEG Ratio: 0.06
• Price to Book (P/B): 5.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.35
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: 0.19p ▼(-19.13% Downside)

The score is primarily weighed down by weak financial performance (no revenue, persistent losses, and ongoing cash burn), which dominates the assessment. Technicals are also soft with the stock trading below key shorter-term averages and negative MACD, only partially offset by near-oversold readings. Valuation signals are limited because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Very low leverage / no debt

A debt-free balance sheet materially reduces solvency risk and preserves strategic flexibility. Over the next several months this allows management to pursue licensing or partnership discussions without near-term interest obligations, supporting financing optionality and downside protection.

Lean operating footprint

A very small headcount keeps fixed overhead and burn low, helping stretch available cash and enabling the company to allocate limited resources to core R&D and partner outreach. This structural nimbleness supports survival while seeking non-dilutive partnerships or financing.

Focused repurposing strategy

A strategy centered on reformulating approved drugs can shorten development timelines and reduce clinical risk versus new chemical entities. That focus increases the likelihood of partnering/licensing for later-stage development and commercialization, a durable pathway to value.

Negative Factors

Zero recent revenue

The absence of meaningful revenue indicates the company has not commercialized products and lacks operating cash inflows. Structurally, this prevents internal funding of R&D and operations, forcing reliance on external capital and complicating sustainable growth planning over coming months.

Consistent negative cash flow

Persistent negative operating and free cash flow shows cash burn is structural rather than episodic. With cash outflows worsening in 2025 after a temporary improvement, the company will likely need recurring financings, which can dilute shareholders and constrain long-term R&D pacing.

Eroded equity and small asset base

Material shrinkage of equity and assets reduces the firm’s financial resilience. A small balance sheet offers limited buffer against development setbacks, weakens negotiating leverage with partners, and increases the urgency of external funding, raising long-term execution risk.

Nuformix Plc Business Overview & Revenue Model

Company Description

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

How the Company Makes Money

Nuformix Plc generates revenue through the development and licensing of its proprietary cocrystal technology to pharmaceutical partners. The company partners with other pharmaceutical organizations to co-develop drugs, sharing in the costs and revenues associated with these products. Additional revenue streams include milestone payments and royalties from successful commercialization of the drugs using their technology. Significant partnerships with larger pharmaceutical firms help in leveraging Nuformix's technology, providing a pathway to market for their innovations and contributing to its earnings.

Nuformix Plc Financial Statement Overview

Summary

Income statement and cash flow are weak due to zero recent revenue, ongoing net losses, and consistently negative free cash flow (continued cash burn). The main offset is a low-risk capital structure with no debt, but the shrinking equity and asset base reduces financial resilience.

Income Statement

The company has not generated meaningful revenue in recent years (revenue is £0 in 2023–2025 annual reports, versus £535k in 2020), indicating a weak or stalled commercialization profile. Profitability is consistently negative, with ongoing operating losses and net losses each year (e.g., net loss of ~£0.65m in 2025 and ~£3.64m in 2024). While the 2025 loss is much smaller than 2024 (suggesting cost tightening or one-off effects), the business remains structurally loss-making and lacks a clear revenue rebound in the provided data.

Balance Sheet

Leverage is very low (total debt is £0 in 2021–2025, and modest in 2020), which reduces financial risk and provides flexibility. However, the equity base has declined materially from 2021–2023 levels to ~£0.75m in 2025, reflecting cumulative losses and/or balance sheet actions, and total assets have similarly stepped down to ~£1.02m in 2025. Overall, the balance sheet is not debt-burdened, but it appears significantly smaller and potentially more fragile than in prior years.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow negative every year shown (e.g., free cash flow of about -£0.61m in 2025 and -£0.33m in 2024). Cash burn fluctuates, improving in 2024 versus 2023 but worsening again in 2025, indicating limited consistency in cash discipline. With losses and ongoing cash outflows, the company likely remains dependent on external funding to sustain operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	50.00K	195.55K
Gross Profit	-28.63K	-28.63K	0.00	-36.75K	11.33K	86.72K
EBITDA	-270.22K	-631.94K	-477.19K	-581.90K	-1.23M	-1.28M
Net Income	-652.59K	-652.59K	-3.64M	-572.98K	-1.11M	-1.25M
Balance Sheet
Total Assets	1.02M	1.02M	970.54K	4.42M	4.98M	6.01M
Cash, Cash Equivalents and Short-Term Investments	97.55K	97.55K	20.21K	202.55K	464.10K	1.67M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	263.92K	263.92K	254.97K	222.99K	237.86K	324.62K
Stockholders Equity	754.93K	754.93K	715.57K	4.20M	4.74M	5.69M
Cash Flow
Free Cash Flow	-223.95K	-614.61K	-331.88K	-397.49K	-1.35M	-848.83K
Operating Cash Flow	-223.95K	-614.61K	-331.88K	-397.49K	-1.35M	-848.22K
Investing Cash Flow	0.00	0.00	0.00	33.33K	0.00	43.72K
Financing Cash Flow	691.95K	691.95K	149.54K	189.79K	139.98K	1.93M

Nuformix Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:NFX, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.27, and above the 200-day MA of 0.18, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 28.92 is Positive, neither overbought nor oversold. The STOCH value of 9.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:NFX.

Nuformix Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£7.67M	-0.64	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HEMO	47 Neutral	£44.46M	-3.32	-609.30%	―	―	―
NFX	46 Neutral	£4.01M	-4.75	-153.80%	―	―	-616.67%
IMM	46 Neutral	£31.97M	-7.15	-259.88%	―	―	―
TCF	45 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
OPTI	43 Neutral	£7.49M	-51.79	-2.42%	―	―	―

Nuformix Plc Corporate Events

Nuformix Sharpens Focus on Partnering Lead IPF Drug NXP002 as Preclinical Data Strengthen Case

In its annual results for the year to 30 September 2025, Nuformix highlighted its strategic focus on securing a business development partner for NXP002, its lead preclinical asset – a patent-protected, inhaled form of tranilast being developed as a novel treatment for idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and other fibrosing interstitial lung diseases. The company reported a series of encouraging preclinical data sets showing that NXP002 can be effectively delivered to the deep lung via nebulisation, is well tolerated at high doses in vivo and ex vivo, and delivers strong anti-fibrotic and anti-inflammatory effects both as a monotherapy and in combination with current standards of care, with additive benefits that suggest action on additional disease pathways. Further studies indicated that NXP002 achieves a durable anti-inflammatory effect consistent with a twice-daily dosing profile and demonstrates a clear dose response across key fibrotic biomarkers in human lung tissue models, strengthening its positioning as a potentially differentiated inhaled therapy in a rapidly growing IPF/PPF market and supporting Nuformix’s ongoing discussions with potential licensing and development partners.

Nuformix PLC Updates Total Voting Rights Following New Share Issuance

Nuformix PLC has announced the issuance of new ordinary shares, confirming its total voting rights as 2,109,749,903 shares, each carrying one voting right. This update aligns with the FCA’s Disclosure Guidance and Transparency Rules, providing shareholders with the necessary information to assess their interests in the company. This development is part of the company’s strategic financial management and may influence stakeholder decisions regarding shareholding notifications.

Nuformix Awaits FDA Response on Orphan Drug Designation for IPF Treatment

Nuformix plc has announced that the US FDA has requested further clarification on a specific element of its Orphan Drug Designation application for tranilast, part of its NXP002 programme targeting Idiopathic Pulmonary Fibrosis (IPF). The company plans to respond promptly using existing data, and remains optimistic about a successful outcome. Meanwhile, Nuformix is in discussions with potential licensing partners, indicating ongoing strategic efforts to advance its market position.

Nuformix plc Successfully Completes Oversubscribed Open Offer

Nuformix plc announced the results of its underwritten Open Offer, which closed on November 11, 2025. The offer was oversubscribed with valid acceptances for 465,813,047 shares, representing a take-up of approximately 408.5% of the available shares. The company will issue 114,040,535 shares, raising approximately £228,081 before expenses. This successful capital raise is expected to enhance Nuformix’s financial position and support its ongoing development efforts in the pharmaceutical sector.